These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7304086)

  • 1. Hormonal pattern in prostatic cancer. II. Correlation with primary response to endocrine treatment.
    Adlercreutz H; Rannikko S; Kairento AL; Karonen SL
    Acta Endocrinol (Copenh); 1981 Dec; 98(4):634-40. PubMed ID: 7304086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of endocrine therapy on plasma steroids in prostatic carcinoma patients.
    Drafta D; Proca E; Schindler AE; Neacşu E; Zamfir V; Neagoe M; Teodosiu D
    Endocrinologie; 1984; 22(3):191-7. PubMed ID: 6494786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal pattern in prostatic cancer. I. Correlation with local extent of tumour, presence of metastases and grade of differentiation.
    Rannikko S; Kairento AL; Karonen SL; Adlercreutz H
    Acta Endocrinol (Copenh); 1981 Dec; 98(4):625-33. PubMed ID: 7304085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of endocrine treatment on serum steroids in advanced prostatic carcinoma patients.
    Lukkarinen O; Hammond GL; Kontturi M; Vihko R
    Invest Urol; 1980 Jan; 17(4):328-31. PubMed ID: 6444293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single drug polyestradiol phosphate therapy in prostatic cancer.
    Stege R; Carlström K; Collste L; Eriksson A; Henriksson P; Pousette A
    Am J Clin Oncol; 1988; 11 Suppl 2():S101-3. PubMed ID: 3242384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
    Grande M; Carlström K; Rozell BL; Stege R; Pousette A
    Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical studies on endocrine therapy of prostatic carcinoma (1): Multivariate analyses of prognostic factors in patients with prostatic carcinoma given endocrine therapy].
    Kumamoto Y; Tsukamoto T; Umehara T; Shimazaki J; Fuse H; Ohshima H; Takeuchi H; Yoshida O; Okada K; Saito Y
    Hinyokika Kiyo; 1990 Mar; 36(3):275-84. PubMed ID: 2191569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
    Lindstedt E
    Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary oxalate excretion during anti-androgenic therapy.
    Tiselius HG; Varenhorst E; Carlström K; Larsson L
    Invest Urol; 1980 Sep; 18(2):110-1. PubMed ID: 6447675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostatic carcinoma cured with hormonal treatment. A report of two cases.
    Johansson S; Ljunggren E
    Scand J Urol Nephrol; 1981; 15(3):321-2. PubMed ID: 7323757
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term effects of endocrine treatment on serum pituitary hormones in advanced prostatic carcinoma patients.
    Lukkarinen O; Hammond GL; Kontturi M; Vihko R
    Scand J Urol Nephrol; 1981; 15(3):207-11. PubMed ID: 6275498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aminoglutethimide in the treatment of advanced prostatic cancer].
    Bauer HW; Schmeller NT; Schmiedt E
    Urologe A; 1985 Jan; 24(1):46-8. PubMed ID: 4039084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment hormone levels in prostatic cancer.
    Haapiainen R; Rannikko S; Alfthan O; Adlercreutz H
    Scand J Urol Nephrol Suppl; 1988; 110():137-43. PubMed ID: 3187401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between clinical response to hormone therapy and steroid receptor content in prostatic cancer.
    Gustafsson JA; Ekman P; Snochowski M; Zetterberg A; Pousette A; Högberg B
    Cancer Res; 1978 Nov; 38(11 Pt 2):4345-8. PubMed ID: 698975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thyroid hormones in metastasizing prostate cancer treated with polyestradiol phosphate].
    Dunzendorfer U; Schulz H
    Z Urol Nephrol; 1982 Jul; 75(7):493-500. PubMed ID: 6183845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endocrine treatment of prostatic cancer. A renaissance for parenteral estrogen].
    Stege R; Sander S
    Tidsskr Nor Laegeforen; 1993 Mar; 113(7):833-5. PubMed ID: 8480286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcapsular orchidectomy in the management of prostatic carcinoma in Nigerians.
    Magoha GA
    East Afr Med J; 1989 Jun; 66(6):400-3. PubMed ID: 2791945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate).
    Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Aro J; Ervasti J; Hansson E; Hurme K; Juusela H; Mäkinen J
    Ann Chir Gynaecol; 1985; 74(6):277-83. PubMed ID: 4096480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer.
    Mikkola AK; Aro JL; Rannikko AS; Ruutu ML;
    BJU Int; 2008 May; 101(9):1090-5. PubMed ID: 18070186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.